Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.

Saved in:
Bibliographic Details
Title: Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.
Authors: Dhir A; Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida., Hayashi M; Department of Pediatrics, University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders Children's Hospital Colorado, Aurora, Colorado., Bodlak A; Department of Pediatrics, University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders Children's Hospital Colorado, Aurora, Colorado., Oesterheld J; Cancer and Blood Disorders Program, Atrium Health Levine Children's Hospital, Charlotte, North Carolina., Loeb DM; Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York.; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York., Mascarenhas L; Cedar-Sinai Medical Center, Guerin Children's and Cedar-Sinai Cancer, Los Angeles, California., Isakoff MS; Division of Hematology/Oncology, Connecticut Children's Medical Center, Hartford, Connecticut., Sandler ES; Division of Hematology/Oncology, Nemours Children's Health, Jacksonville, Florida., Borinstein SC; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Trucco M; Department of Pediatric Hematology-Oncology and BMT, Cleveland Clinic Children's, Cleveland, Ohio., Lagmay JP; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Shands Childrens Hospital, University of Florida, Gainesville, Florida., Setty BA; Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio., Pratilas CA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Caywood E; Division of Hematology/Oncology, Nemours Children's Health, Jacksonville, Florida., Metts J; Sarcoma Department, Moffitt Cancer Center, Tampa, Florida.; Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Peterburg, Florida., Yin H; Department of Pathology, Children's Healthcare of Atlanta, Atlanta, Georgia., Fridley B; Health Services and Outcomes Research, Children's Mercy Hospital, Kansas City, Missouri., Yin J; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida., Laborde J; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida., Reed DR; Moffitt Cancer Center, Department of Individualized Cancer Management, Tampa, Florida., Adams DL; Creatv Microtech, Monmouth Junction, New Jersey., Wagner LM; Division of Pediatric Hematology/Oncology, Duke University, Durham, North Carolina.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 02; Vol. 30 (23), pp. 5314-5322.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-1339